Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin.

Détails

ID Serval
serval:BIB_5CA5398BF65A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin.
Périodique
Journal of Thrombosis and Haemostasis : Jth
Auteur(s)
Evangelista V., de Berardis G., Totani L., Avanzini F., Giorda C.B., Brero L., Levantesi G., Marelli G., Pupillo M., Iacuitti G., Pozzoli G., di Summa P., Nada E., de Simone G., Dell'Elba G., Amore C., Manarini S., Pecce R., Maione A., Tognoni G., Nicolucci A.
ISSN
1538-7933 (Print)
ISSN-L
1538-7836
Statut éditorial
Publié
Date de publication
2007
Volume
5
Numéro
11
Pages
2197-2203
Langue
anglais
Notes
Publication types: Controlled Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
BACKGROUND: The percentage of diabetic patients who do not benefit from the protective effect of aspirin is larger than in other populations at cardiovascular risk.
OBJECTIVE: We compared the ability of aspirin to suppress TxA2 and platelet activation in vivo, in type-2 diabetics vs. high-risk non-diabetic patients.
METHODS: Urinary 11-dehydro-TXB2, plasma sCD40 L, and sP-selectin were measured, together with indices of low-grade inflammation, glycemic control, and lipid profile, in 82 patients with type-2 diabetes and 39 without diabetes, treated with low doses of aspirin.
RESULTS: Urinary 11-dehydro-TxB2, plasma sCD40L and sP-selectin were significantly higher in diabetics than in controls: [38.9 (27.8-63.3) vs. 28.5 (22.5-43.9) ng mmol(-1) of creatinine, P = 0.02], [1.06 (0.42-3.06) vs. 0.35 (0.22-0.95) ng mL(-1); P = 0.0001], [37.0 (16.8-85.6) vs. 20.0 (11.2-35.6) ng mL(-1), P = 0.0001], respectively. The proportion of individuals with diabetes increased across quartiles of 11-dehydro-TxB2, sCD40L, and sP-selectin, with the highest quartiles of 11-dehydro-TxB2, sCD40L and sP-selectin, including 66%, 93.3%, and 93.3% of individuals with diabetes. Markers of platelet activation positively correlated with indices of glycemic control but not with markers of low-grade inflammation.
CONCLUSIONS: Platelet dysfunction associated with insufficient glycemic control, may mediate persistent platelet activation under aspirin treatment.
Mots-clé
Aspirin/pharmacology, Aspirin/therapeutic use, Biomarkers/blood, Blood Glucose, Case-Control Studies, Diabetes Mellitus, Type 2/blood, Diabetes Mellitus, Type 2/drug therapy, Glycemic Index, Humans, Inflammation, Platelet Activation/drug effects, Thromboxane A2/antagonists & inhibitors
Pubmed
Web of science
Open Access
Oui
Création de la notice
10/10/2016 9:01
Dernière modification de la notice
02/06/2020 6:26
Données d'usage